I was doing some research on Robinhood day trading when I learned something quite fascinating.
Apparently, the real story about legendary outlaw Robin Hood is vastly different from the one I was told as a child.
You know the story…
He robbed from the rich and gave to the poor.
Folks portrayed him as a hero. But as I grew older, I understood that such a thing lends itself to the violent nature of socialism. So I rejected the concept of Robin Hood being a “hero.”
Although it turns out, I was way off. Our analysts have traveled the world over, dedicated to finding the best and most profitable investments in the global energy markets. All you have to do to join our Energy and Capital investment community is sign up for the daily newsletter below.
Word is, Robin Hood didn’t steal from the rich. He stole from the king and his loyalists. And when he “gave to the poor,” he was actually returning their stolen goods.
How can anyone not love that?!!
As a liberty-minded advocate recently put it, what Robin Hood did was not an act of charity or redistribution of wealth. It was a rebellion against the state.
Of course with this revelation, I can’t help but think about the very popular trading app, RobinHood (NASDAQ: HOOD).
Robinhood pitches itself as some sort of altruistic trading alternative designed to “democratize finance for all.”
A sort of modern-day “Robin Hood” designed to look out for the little guy.
But is it true?
Stuff like that always seems suspect to me. Especially in the case of this particular company.
The Pros and Cons of Robinhood Day Trading
You may recall a few years ago when the app froze all trading on GameStop (NYSE: GME).
There were some questionable circumstances surrounding that decision. But make no mistake: what happened was not an example of “democratization” or “looking out for the little guy.”
That being said, things have become a lot easier for amateur traders using the Robinhood day trading app. And that’s a good thing. How could I oppose a company that helps regular folks build wealth?
Of course, to really make a lot of money, you need more than just the Robinhood day trading app. You need access to up-to-the-minute, and well-vetted intel. Because without it, you risk far more than what you can gain.
And boy, you can gain a hell of a lot if you’re getting a steady stream of solid intel.
Take, for instance, the intel I provided on a couple of biotech stocks regarding their progress on their FDA clinical trials.
Two companies in particular are running clinical trials on a new class of medications called EN-23. It’s actually one of the biggest breakthroughs medical science has seen in 50 years. Not just because it successfully treats mental health conditions such as depression, anxiety, PTSD and addiction. But also because it could help you extend your lifespan by up to 20 years.
Now the FDA has a special designation for drugs that treat life-threatening conditions, as long as the evidence indicates those drugs demonstrate substantial improvement over currently available treatments.
I knew these two companies met all the qualifications to meet this particular designation. It’s called “breakthrough status.” And for the past two years I’ve been monitoring their progress.
When it became clear that both of these companies would qualify for “breakthrough status,” I put out a buy alert. Because if you know anything about biotech stocks, you know that this designation means the FDA will fast-track clinical trials. And nothing sends a biotech stock to the moon faster than a fast-tracked clinical trial.
And that’s exactly what happened.
The first was a stock called MindMed (NASDAQ: MNMD). It soared nearly 90% on the news that it was granted “breakthrough status” by the FDA. Check it out…
Then, just a few days later, it happened again. This time with a stock called Cybin (NYSE: CYBN). That one soared 37% in a matter of hours.
Now I don’t know if they used this intel and profited handsomely using the Robinhood day trading app. But no matter which trading platform they used, they made a lot of money. And here’s the best part…
There are nearly a dozen more EN-23 companies that could also get “breakthrough status” designation this year. And I’ve written about a few of those stocks here.
If you’re looking for a few easy scores as a day trader, you won’t do better than playing FDA approvals. And if you don’t believe it, just look at the numbers for yourself.
To a new way of life and a new generation of wealth… Jeff Siegel
@JeffSiegel on Twitter
Check us out on YouTube!Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor’s page.
Want to hear more from Jeff? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on.
